
CytoReason Raises $80M to Expand AI Disease Models, Launch US Hub
CytoReason, a pioneer in computational disease models for predictive insights, has secured $80 million from OurCrowd, NVIDIA (Nasdaq: NVDA), Pfizer (NYSE: PFE), and Thermo Fisher Scientific (NYSE: TMO). “This investment underscores the potential of computational disease models to revolutionize data…












